Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$15.74 -3.0%	$14.25	$9.57 ▼ $30.41	$2.17B	0.96	1.53 million shs	1.22 million shs
KNSA Kiniksa Pharmaceuticals	$28.30 +2.1%	$25.12	$17.38 ▼ $30.69	$2.07B	0.06	515,189 shs	907,293 shs
MRVI Maravai LifeSciences	$2.13 -5.8%	$2.07	$1.67 ▼ $10.03	$542.43M	0.25	2.33 million shs	992,677 shs
NAMS NewAmsterdam Pharma	$20.21 -3.9%	$18.19	$14.06 ▼ $27.29	$2.27B	-0.03	679,365 shs	550,120 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-2.96%	-6.37%	+5.57%	+2.47%	-38.92%
KNSA Kiniksa Pharmaceuticals	+2.06%	-6.38%	+13.06%	+25.17%	+49.50%
MRVI Maravai LifeSciences	-5.75%	-10.88%	+7.58%	-13.06%	-72.97%
NAMS NewAmsterdam Pharma	-3.90%	+0.35%	+7.79%	-13.52%	+2.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.5995 of 5 stars	3.4	1.0	3.4	2.7	2.5	0.0
KNSA Kiniksa Pharmaceuticals	3.2534 of 5 stars	3.5	3.0	0.0	3.0	3.3	0.6
MRVI Maravai LifeSciences	4.0092 of 5 stars	3.1	3.0	4.4	2.0	0.8	1.3
NAMS NewAmsterdam Pharma	2.964 of 5 stars	3.5	2.0	0.0	2.6	5.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	177.73% Upside
KNSA Kiniksa Pharmaceuticals	3.00	Buy	$38.80	37.10% Upside
MRVI Maravai LifeSciences	2.25	Hold	$6.64	211.68% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$43.00	112.77% Upside

Current Analyst Ratings Breakdown

Latest MRVI, ARWR, NAMS, and KNSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/13/2025	MRVI Maravai LifeSciences	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
5/13/2025	MRVI Maravai LifeSciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$3.00 ➝ $2.00
5/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
4/29/2025	KNSA Kiniksa Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00
4/16/2025	KNSA Kiniksa Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$34.00 ➝ $34.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$545.21M	3.99	N/A	N/A	$1.54 per share	10.22
KNSA Kiniksa Pharmaceuticals	$481.17M	4.29	N/A	N/A	$6.23 per share	4.54
MRVI Maravai LifeSciences	$241.86M	2.24	$0.05 per share	41.71	$3.14 per share	0.68
NAMS NewAmsterdam Pharma	$47.14M	48.13	N/A	N/A	$3.50 per share	5.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	N/A	N/A	-236.60%	-64.09%	8/6/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals	$14.08M	-$0.25	N/A	113.20	N/A	-2.36%	-7.31%	-5.95%	7/22/2025 (Estimated)
MRVI Maravai LifeSciences	-$119.03M	-$1.14	N/A	N/A	N/A	-81.13%	-6.61%	-3.45%	8/6/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$176.94M	-$1.88	N/A	N/A	N/A	N/A	N/A	N/A	8/6/2025 (Estimated)

Latest MRVI, ARWR, NAMS, and KNSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/12/2025	Q1 2025	MRVI Maravai LifeSciences	-$0.07	-$0.08	-$0.01	-$0.21	$44.01 million	$46.85 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRVI Maravai LifeSciences	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	7.27	6.09	6.09
KNSA Kiniksa Pharmaceuticals	N/A	3.24	2.95
MRVI Maravai LifeSciences	0.89	10.74	9.94
NAMS NewAmsterdam Pharma	N/A	10.61	10.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
KNSA Kiniksa Pharmaceuticals	53.95%
MRVI Maravai LifeSciences	50.25%
NAMS NewAmsterdam Pharma	89.89%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
KNSA Kiniksa Pharmaceuticals	54.57%
MRVI Maravai LifeSciences	2.11%
NAMS NewAmsterdam Pharma	20.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	120.68 million	Optionable
KNSA Kiniksa Pharmaceuticals	220	72.97 million	32.80 million	Optionable
MRVI Maravai LifeSciences	610	254.66 million	250.94 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	74.37 million	Optionable

MRVI, ARWR, NAMS, and KNSA Headlines

Recent News About These Companies

Dr. Reddy's Laboratories (NYSE:RDY) versus NewAmsterdam Pharma (NASDAQ:NAMS) Critical Review

June 14 at 2:05 AM | americanbankingnews.com

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by Handelsbanken Fonder AB

June 13 at 4:34 AM | marketbeat.com

5NAMS : What Analysts Are Saying About NewAmsterdam Pharma...

June 12 at 9:56 AM | benzinga.com

Strong Buy Recommendation for NewAmsterdam Pharma Driven by Promising Cardiovascular and Alzheimer’s Opportunities

June 12 at 8:34 AM | tipranks.com

NewAmsterdam Pharma (NASDAQ:NAMS) Given Buy Rating at Needham & Company LLC

June 12 at 8:30 AM | marketbeat.com

Stifel Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation

June 11 at 11:54 PM | msn.com

NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel

June 11 at 9:25 PM | insidermonkey.com

NewAmsterdam Pharma Rings the Closing Bell

June 11 at 6:53 PM | nasdaq.com

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 4.4% - Should You Sell?

June 11 at 12:56 PM | marketbeat.com

NewAmsterdam Pharma Schedules R&D Day for June 2025

June 11 at 9:43 AM | tipranks.com

NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Stifel Nicolaus

June 11 at 3:09 AM | americanbankingnews.com

Cantor Fitzgerald Forecasts NAMS FY2026 Earnings

June 11 at 2:23 AM | americanbankingnews.com

NewAmsterdam Pharma (NASDAQ:NAMS) Trading 7.5% Higher - Should You Buy?

June 10, 2025 | marketbeat.com

Positive top-line Alzheimer’s disease data from NewAmsterdam

June 10, 2025 | thepharmaletter.com

Analysts Have Just Cut Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Estimates By 14%

June 10, 2025 | finance.yahoo.com

Analysts Offer Predictions for NAMS FY2026 Earnings

June 10, 2025 | marketbeat.com

NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Stifel Nicolaus

June 10, 2025 | marketbeat.com

NewAmsterdam Pharma Shares Rise on Positive Alzheimer's Cholesterol Treatment Data

June 10, 2025 | marketwatch.com

NewAmsterdam links lipid-lowering drug to improvement in Alzheimer's cognition biomarker

June 10, 2025 | fiercebiotech.com

NewAmsterdam says cholesterol drug may also combat Alzheimer’s

June 10, 2025 | biopharmadive.com

NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial

June 10, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI, ARWR, NAMS, and KNSA Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$15.74 -0.48 (-2.96%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$16.25 +0.51 (+3.24%)

As of 06/13/2025 07:11 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Kiniksa Pharmaceuticals NASDAQ:KNSA

$28.30 +0.57 (+2.06%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$27.58 -0.72 (-2.56%)

As of 06/13/2025 07:55 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Maravai LifeSciences NASDAQ:MRVI

$2.13 -0.13 (-5.75%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.12 -0.01 (-0.47%)

As of 06/13/2025 06:24 PM Eastern

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

NewAmsterdam Pharma NASDAQ:NAMS

$20.21 -0.82 (-3.90%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$20.22 +0.01 (+0.05%)

As of 06/13/2025 05:50 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time